Combination of IAP Inhibitors and FLT3 Inhibitors

摘要

The present invention relates to combinations of IAP inhibitors and FLT3 inhibitors, pharmacological compositions comprising the combination, methods of treating hematological malignancies, including acute myeloid leukemia (AML), comprising the combination of a compound that inhibits the binding of the second mitochondria-derived activator of caspase (Smac) protein to inhibitor of apoptosis (IAPs) (IAP inhibitor) and one or more pharmaceutically active agents and the use of these combinations for the treatment of acute myeloid leukemia; and a commercial package comprising the combination.